---
document_datetime: 2024-11-27 14:53:47
document_pages: 60
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/dafiro-hct-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: dafiro-hct-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 109.9402912
conversion_datetime: 2025-12-21 23:23:54.238452
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Dafiro HCT

Proceduralstepstakenandscientificinformationaftertheauthorisation

| Application number   | Scope                                                                                                                                                                                                               | Opinion/ Notification 1 issued on   | Commission Decision Issued2 / amended on   | Product Information affected3   | Summary   |
|----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|--------------------------------------------|---------------------------------|-----------|
| IG/1804              | B.II.b.2.c.1-Change to importer,batch release arrangements andquality controltestingof theFP- Replacementoradditionofamanufacturer responsibleforimportation and/orbatchrelease- Not includingbatch control/testing | 21/11/2024                          |                                            | Annex II and PL                 |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions areissuedforallotherprocedures.

3 SmPC (Summary of Product Characteristics), Annex I, Labelling, PL (Package Leaflet).

2 A Commission decision(CD) is issued for procedures that affect the terms of the marketing authorisation(e.g. summary of product characteristics, annexII, labelling,package leaflet).The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a)of Regulation(Eu)No.712/2012, or within one year for other procedures.

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| WS/2656/G   | Thiswas an applicationfor agroupofvariations followingaworksharingprocedure according to Article20of CommissionRegulation(EC)No 1234/2008. B.I.a.1.f-Change in the manufacturer of AS or of a startingmaterial/reagent/intermediateforAS- Changes to quality control testing arrangements for theAS-replacementoradditionofasitewhere batchcontrol/testingtakesplace B.III.1.a.3-Submission of a new/updated or deletion ofPh.Eur.CertificateofSuitability to the relevantPh.Eur.Monograph-Newcertificatefrom a newmanufacturer(replacementor addition)   | 05/09/2024   | n/a   |             |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-------------|
| IG/1784     | B.III.1.a.2-Submission of a new/updated or deletionofPh.Eur.CertificateofSuitabilitytothe relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                                                                                         | 28/08/2024   | n/a   |             |
| IG/1780     | A.7-Administrative change-Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 16/08/2024   | n/a   |             |
| IG/1708     | B.Ill.1.a.2-Submissionofanew/updatedor deletionofPh.Eur.CertificateofSuitabilitytothe relevantPh.Eur.Monograph-Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                                                                                                  | 08/04/2024   | n/a   |             |
| WS/2609     | Thiswasanapplicationfor avariationfollowinga worksharing procedure according to Article 20 of CommissionRegulation(EC)No1234/2008.                                                                                                                                                                                                                                                                                                                                                                                                                        | 25/01/2024   |       | SmPC and PL |

<div style=\"page-break-after: always\"></div>

|           | C.I.z - Changes (Safety/Efficacy) of Human and VeterinaryMedicinalProducts-Othervariation                                                                                                                                                                                                                                                                                                                                                     |            |            |          |                               |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|-------------------------------|
| IG/1666/G | This was an application for a group of variations. A.4-Administrativechange-Change in thename and/oraddressofamanufactureroranASMFholder orsupplieroftheAS，startingmaterial,reagentor intermediateusedinthemanufactureof theASor manufacturerofanovelexcipient A.4-Administrative change-Change in thename and/oraddressofamanufactureroranASMFholder orsupplieroftheAS，startingmaterial,reagentor intermediateusedinthemanufactureof theASor | 14/09/2023 | n/a        |          | manufacturerofanovelexcipient |
| WS/2513   | This was an application for a variation following a worksharingprocedureaccordingtoArticle20of CommissionRegulation(EC)No1234/2008. C.1.11.z -Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation，includingtheRMP-Othervariation                                                                                                                                                                    | 14/09/2023 | 15/11/2023 | Annex II |                               |
| IG/1645/G | This was an applicationfor a group of variations. A.7-Administrative change-Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.7-Administrativechange-Deletionof                                                                                                                                                                                                                                 | 08/08/2023 | n/a        |          | manufacturing sites           |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| IG/1637   | B.III.1.a.2-Submission of a new/updated or deletion ofPh.Eur.Certificateof Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 19/07/2023   | n/a   |                                                 |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-------------------------------------------------|
| WS/2411/G | This was an applicationfor a group ofvariations following a worksharing procedure according to Article20of CommissionRegulation(EC)No 1234/2008. B.II.b.4.a -Change in the batch size (including batch sizeranges)of thefinishedproduct-Upto10-fold compared to the originally approved batch size B.II.b.4.a -Change in the batch size (including batch size ranges) of the finished product -Up to 10-fold compared to the originally approved batch size B.II.b.3.a-Change in the manufacturingprocess of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.z-Change in the manufacturing process of thefinished orintermediateproduct-Othervariation B.II.b.3.z-Changeinthemanufacturingprocessof thefinishedorintermediateproduct-Othervariation B.II.b.4.a-Change in thebatch size(includingbatch sizeranges)of thefinishedproduct-Upto10-fold compared to the originally approved batch size B.II.b.3.a-Change in the manufacturing process of thefinishedorintermediateproduct-Minorchange inthemanufacturingprocess B.II.b.3.z - Change in the manufacturing process of | 30/03/2023   | n/a   | thefinishedorintermediateproduct-Othervariation |

<div style=\"page-break-after: always\"></div>

|           | B.II.b.4.a - Change in the batch size (including batch sizeranges)of the finishedproduct-Up to10-fold comparedtotheoriginallyapprovedbatchsize B.I1.b.4.a-Changeinthebatchsize(includingbatch size ranges) of the finished product - Up to 10-fold compared to the originally approvedbatch size B.II.b.3.a-Change in themanufacturingprocessof the finished or intermediate product - Minor change inthemanufacturingprocess   |            |            |                   |                                                                                                                             |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------------|-----------------------------------------------------------------------------------------------------------------------------|
| IG/1604/G | Thiswasanapplicationforagroupofvariations. A.7-Administrative change-Deletion of manufacturing sites A.7-Administrative change-Deletion of manufacturing sites A.7-Administrative change-Deletion of manufacturing sites A.7-Administrative change-Deletion of                                                                                                                                                                  | 21/03/2023 | n/a        |                   |                                                                                                                             |
| WS/2373   | This was an application for a variation following a worksharingprocedureaccording toArticle20of CommissionRegulation(EC)No1234/2008. C.1.11.a-Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation,including theRMP-Implementation of wordingagreedbythecompetentauthority                                                                                                             | 15/12/2022 | 15/11/2023 | SmPC and Annex II | ToupdateAnnexII torequest anextensionof thedue date forthefulfilmentofconditionB,from'26September2022' to'01 0ctober 2023'. |
| WS/2338   | This was an application for a variation following a worksharingprocedureaccordingtoArticle20of                                                                                                                                                                                                                                                                                                                                  | 10/11/2022 | 15/11/2023 | SmPC              | Toupdatesection4.9of theSmPC,toimplementthe wording related to the risk of non-cardiogenic pulmonary                        |

<div style=\"page-break-after: always\"></div>

|           | CommissionRegulation(EC)No1234/2008. C.I.z - Changes (Safety/Efficacy) of Human and VeterinaryMedicinalProducts-Othervariation                                                                                                                                                                                                                                                                                                                                                                                                            |            |     | oedemainamlodipineoverdose.   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------------------|
| WS/2278/G | This was an application for a group of variations following a worksharing procedure according to Article20ofCommissionRegulation(EC)No 1234/2008. B.IIl.1.a.3-Submission of a new/updated or deletionofPh.Eur.CertificateofSuitabilitytothe relevantPh.Eur.Monograph-New certificate from a newmanufacturer(replacement or addition) B.I.a.1.f-Change in themanufacturer of ASor of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where | 27/10/2022 | n/a |                               |
| IG/1523   | A.7-Administrative change-Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 22/06/2022 | n/a |                               |
| WS/2256/G | Thiswasanapplicationforagroupofvariations following aworksharingprocedure according to Article20of CommissionRegulation(EC)No 1234/2008. B.III.1.a.2-Submission of a new/updated or deletionofPh.Eur.CertificateofSuitabilitytothe relevantPh.Eur.Monograph-Updated certificate from an already approved manufacturer                                                                                                                                                                                                                     | 02/06/2022 | n/a |                               |

<div style=\"page-break-after: always\"></div>

|         | B.I.b.1.c-Change in the specificationparameters and/or limits of an AS, starting material/intermediate/reagent-Additionof anew specification parameter to the specification with its corresponding test method B.I.b.2.a - Change in test procedure for AS or startingmaterial/reagent/intermediate-Minor changes to an approved test procedure B.I.b.2.a-Change in test procedure forAS or startingmaterial/reagent/intermediate-Minor changes to an approved test procedure B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changestoa testprocedure(includingreplacement or addition) for the AS or a starting material/intermediate B.I.b.2.e -Change in test procedure forAS or starting material/reagent/intermediate - Other changestoa testprocedure(includingreplacement or addition) for the AS or a starting material/intermediate B.I.a.1.f-Change in the manufacturer of AS or of a startingmaterial/reagent/intermediateforAS- Changestoqualitycontrol testing arrangementsfor theAS-replacement oradditionofasitewhere   |            |            |             |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|
| WS/2237 | This was an application for a variation following a worksharing procedure according to Article 20 of CommissionRegulation(EC)No1234/2008. C.I.z - Changes (Safety/Efficacy) of Human and                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 31/03/2022 | 02/09/2022 | SmPC and PL |

<div style=\"page-break-after: always\"></div>

|                     | VeterinaryMedicinalProducts-Othervariation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |            |                            |                                                                                                                                                                         |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10344 /202106 | Periodic Safety Update EU Single assessment - amlodipine / valsartan, amlodipine / hydrochlorothiazide/valsartan                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 10/02/2022 | n/a        |                            | PRACRecommendation-maintenance                                                                                                                                          |
| WS/2207             | This was an application for a variation following a worksharingprocedure according toArticle20of CommissionRegulation(EC)No1234/2008. TobringtheannexesinlinewiththecurrentQRD templatev10.2.InadditiontheMAH hastaken the opportunity to update the local contact details for the UK (Northern Ireland). C.I.z - Changes (Safety/Efficacy) of Human and                                                                                                                                                                                                                               | 03/02/2022 | 02/09/2022 | Annex II, Labelling and PL | Tobring the annexes inlinewith the current QRDtemplate v10.2. In addition the MAH has taken the opportunity to updatethelocal contactdetailsfortheUK(Northern Ireland). |
| IG/1440/G           | Thiswas an applicationfor a group of variations. B.IIl.1.a.2-Submission of a new/updated or deletionofPh.Eur.Certificate ofSuitabilityto the relevant Ph.Eur.Monograph-Updated certificate fromanalreadyapprovedmanufacturer A.4-Administrative change-Change in the name and/oraddressof amanufactureror anASMFholder orsupplierof theAS，startingmaterial,reagentor intermediateusedinthemanufactureof theASor manufacturer of a novel excipient A.4-Administrative change-Change in the name and/oraddressofamanufactureroranASMFholder orsupplieroftheAS，startingmaterial,reagentor | 29/11/2021 | n/a        |                            |                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

|           | intermediateused in themanufacture of theASor manufacturerofanovelexcipient                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |            |                 |         |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|---------|
|           | Thiswas an applicationfor avariationfollowing a worksharingprocedureaccordingtoArticle20of CommissionRegulation(EC)No1234/2008. C.1.11.z -Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation,including the RMP-Othervariation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 02/09/2021 | 02/09/2022 | Annex II        | WS/2109 |
| WS/2090/G | Thiswas an applicationfor agroupofvariations followingaworksharingprocedure accordingto Article20of CommissionRegulation(EC)No 1234/2008. B.1I.b.2.c.1-Change to importer,batch release arrangements and quality control testing of the FP - Replacementoradditionofamanufacturer responsibleforimportation and/orbatchrelease- Notincludingbatchcontrol/testing A.5.b-Administrative change -Change in the name and/or addressofamanufacturer/importerofthe finishedproduct,including quality control sites (excludingmanufacturerforbatchrelease) B.II.e.4.a-Change in shape ordimensions of the container or closure (immediate packaging) - Non- sterile medicinal products B.II.b.3.z - Change in the manufacturing process of thefinished orintermediateproduct-Other variation B.II.b.2.c.2-Change to importer,batch release | 02/09/2021 | 02/09/2022 | Annex II and PL |         |

<div style=\"page-break-after: always\"></div>

|         | Including batch control/testing B.II.b.1.e-Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release,batchcontrol,primaryandsecondary packaging,fornon-sterilemedicinalproducts                                                                                                                |            |            |          |                                                |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|------------------------------------------------|
|         | Thiswas an applicationfor a group of variations. C.1.11.a -Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation,includingtheRMp-Implementationof wording agreed by the competent authority C.1.11.a-Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation,including theRMP-Implementation of | 26/04/2021 | 17/06/2021 | Annex II | IG/1383/G wordingagreedbythecompetentauthority |
| WS/2019 | This was an application for a variation following a worksharing procedure according to Article 20 of CommissionRegulation(EC)No1234/2008. B.I.b.1.h -Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionor replacement(excl.Biol.orimmunol.substance)ofa specification parameter as a result of a safety or        | 15/04/2021 | n/a        |          | quality issue                                  |
|         | Thiswas anapplicationfor agroupofvariations following a worksharing procedure according to Article20of CommissionRegulation(EC)No                                                                                                                                                                                                                                             | 15/04/2021 | n/a        |          | WS/2022/G                                      |

<div style=\"page-break-after: always\"></div>

|          | 1234/2008. B.I.b.1.c-Change in the specification parameters and/or limits of anAS,starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its correspondingtestmethod B.I.b.1.c-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.Ill.1.a.2-Submissionofanew/updatedor deletionofPh.Eur.CertificateofSuitabilitytothe relevantPh.Eur.Monograph-Updated certificate from an already approvedmanufacturer                                                           |            |            |          |                                                                              |
|----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|------------------------------------------------------------------------------|
| A31/0070 | The European Commission triggered a referral under Article31ofDirective2001/83/ECandrequestedthe CHMP to assess the impact of nitrosamine impurities on the benefit-risk balance of valsartan-containing medicinalproductsandtoissue arecommendation onwhethertherelevantmarketingauthorisations shouldbe maintained,varied,suspended orrevoked. During theCHMPplenarymeetinginSeptember 2018, the scope of the referral has been widened to includeallsartanswithatetrazolegroupintheir molecular structure (candesartan, irbesartan, losartan, olmesartan and valsartan).The CHMP Opinion was issued on 31 January 2019 and the CommissionDecisionwasissuedon11April2019. | 12/11/2020 | 19/02/2021 | Annex II | Please refer to the assessment report: DafiroHCTEMEA/H/A-31/1471/C/1160/0070 |

<div style=\"page-break-after: always\"></div>

|         | CommissionrequestedtheEMA toassess theimpact of theoutcome of theArticle5(3)assessment on nitrosaminesadoptedon25June2020on the CHMP'sopinionof31January2019forthescientific assessmentandreviewunderArticle31ofDirective 2001/83/ECregardingangiotensin-II-receptor antagonists (sartans) containing a tetrazole group (EMEA/H/A-31/1471).The CHMPwasrequested to give its recommendation whether the conditions of the Marketing Authorisations should bevaried.   |            |            |          |           |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|-----------|
| IG/1325 | A.4-Administrative change-Change in the name and/or address of a manufacturer or an ASMF holder orsupplieroftheAS，startingmaterial,reagentor intermediateused in themanufacture of theASor manufacturerofanovelexcipient                                                                                                                                                                                                                                             | 06/01/2021 | n/a        |          |           |
| IG/1318 | B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information                                                                                                                                                                                                                                                                                       | 07/12/2020 | n/a        |          |           |
|         | Thiswas an applicationfor a group of variations. A.4-Administrative change-Change in the name and/oraddressof amanufactureror anASMFholder orsupplieroftheAS，startingmaterial,reagentor intermediateusedinthemanufactureoftheASor manufacturerofanovelexcipient B.I.a.1.f-Change in the manufacturer of AS or of a                                                                                                                                                   | 21/10/2020 | 17/06/2021 | Annex II | IB/0089/G |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for theAS-replacementoradditionofasitewhere batch control/testing takes place B.I.b.1.h-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionor replacement(excl. Biol. or immunol. substance) of a specification parameter as a result of a safety or quality issue B.I.b.2.e-Change in test procedure forAS or starting material/reagent/intermediate - Other changestoa testprocedure(includingreplacement or addition) for the AS or a starting material/intermediate B.I.b.2.z-Change in test procedure forAS or startingmaterial/reagent/intermediate-Other variation B.III.1.a.2-Submission of a new/updated or deletionofPh.Eur.CertificateofSuitabilityto the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.III.1.a.2-Submission of a new/updated or deletion ofPh.Eur.CertificateofSuitability to the relevant Ph.Eur.Monograph-Updated certificate from an already approved manufacturer B.Ill.1.a.2-Submissionofanew/updatedor deletionofPh.Eur.CertificateofSuitabilitytothe relevantPh.Eur.Monograph-Updated certificate from an already approved manufacturer B.III.1.a.2-Submission of a new/updated or   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|         | relevant Ph. Eur. Monograph - Updated certificate from an already approvedmanufacturer B.II1.1.a.3-Submission of a new/updated or deletionofPh.Eur.CertificateofSuitabilityto the relevant Ph. Eur. Monograph - New certificate from a newmanufacturer(replacementor addition)                                                                                                                                                                                |            |            |             |                                          |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------|
|         | C.I.z-Changes(Safety/Efficacy)of Human and VeterinaryMedicinalProducts-Othervariation                                                                                                                                                                                                                                                                                                                                                                         | 23/06/2020 | 17/06/2021 | SmPC and PL | IG/1255                                  |
|         | This was an applicationfor a group ofvariations. A.4-Administrative change-Change in the name and/oraddressofamanufactureroranASMFholder orsupplieroftheAS,startingmaterial,reagentor intermediateusedinthemanufactureoftheASor manufacturer of a novel excipient B.I.a.1.f-Change in themanufacturer ofASor of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for theAS-replacementoradditionofasitewhere | 15/05/2020 | n/a        |             | IG/1254/G batchcontrol/testingtakesplace |
| IG/1207 | B.Ill.1.a.2-Submissionofanew/updatedor deletionofPh.Eur.CertificateofSuitabilitytothe relevantPh.Eur.Monograph-Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                      | 31/01/2020 | n/a        |             |                                          |
|         | Thiswas anapplicationfor a groupofvariations. B.I.a.1.f-ChangeinthemanufacturerofASorofa starting material/reagent/intermediate for AS -                                                                                                                                                                                                                                                                                                                      | 19/12/2019 | n/a        |             | IG/1179/G                                |

<div style=\"page-break-after: always\"></div>

| Changestoqualitycontroltesting arrangementsfor theAS-replacementoradditionofasitewhere batchcontrol/testingtakesplace B.I.a.1.f-Change in the manufacturer ofASor of a starting material/reagent/intermediate for AS - Changestoqualitycontroltestingarrangementsfor theAS-replacementoradditionofasitewhere batchcontrol/testingtakesplace B.III.1.a.1 -Submission of a new/updated or deletion ofPh.Eur.Certificateof Suitability to the relevant Ph.Eur.Monograph-New certificate from an already approved manufacturer B.Ill.1.a.2-Submissionofanew/updatedor deletionofPh.Eur.CertificateofSuitabilitytothe relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer   |            |     |           |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------|
| This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/oraddressof amanufacturer/importerofthe finished product, including quality control sites (excluding manufacturer for batch release) A.7-Administrativechange-Deletionof manufacturing sites A.7-Administrativechange-Deletionof manufacturingsites B.II.b.2.a-Change to importer,batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testingtakesplace                                                                                                                                                                        | 11/12/2019 | n/a | IG/1175/G |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| WS/1656/G   | Thiswas anapplicationfor agroupofvariations                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 31/10/2019   | 18/06/2020   | Annex II   |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------|
|             | following a worksharing procedure according to Article20of CommissionRegulation(EC)No 1234/2008. B.I.a.1.f -Change in the manufacturer of AS or of a startingmaterial/reagent/intermediateforAS- Changes to quality control testing arrangements for theAS-replacementoradditionofasitewhere batchcontrol/testing takesplace B.I.a.1.f -Change in the manufacturer of AS or of a startingmaterial/reagent/intermediateforAS- Changestoqualitycontroltestingarrangementsfor theAS-replacementoradditionofasitewhere batchcontrol/testingtakesplace B.I.b.1.h - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Addition or replacement(excl.Biol.orimmunol.substance)ofa specification parameter as a result of a safety or quality issue B.I.b.1.h-Change in the specificationparameters and/or limits of an AS, starting material/intermediate/reagent-Addition or replacement (excl. Biol. or immunol. substance) of a specification parameter as a result of a safety or quality issue B.I.b.2.a-Change in testprocedure forAS or startingmaterial/reagent/intermediate-Minor changes to an approved test procedure B.I.b.2.z - Change in test procedure for AS or |              |              |            |

<div style=\"page-break-after: always\"></div>

|           | variation                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |            |                                  |           |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------|
| IG/1148   | B.IIl.1.a.4-Submission of a new/updated or deletion ofPh.Eur.CertificateofSuitability to the relevantPh.Eur.Monograph-Deletion of certificates (in case multiplecertificatesexistper material)                                                                                                                                                                                                                                                                 | 04/10/2019 | n/a        |                                  |           |
|           | Thiswas an applicationfor a group of variations. B.I.a.1.f-Change in the manufacturer of AS or of a startingmaterial/reagent/intermediateforAS- Changestoqualitycontroltestingarrangementsfor theAS-replacementoradditionofasitewhere batch control/testing takes place B.III.1.a.3-Submission of a new/updated or deletionofPh.Eur.CertificateofSuitabilityto the relevant Ph. Eur. Monograph - New certificate from a newmanufacturer(replacementoraddition) | 08/08/2019 | n/a        |                                  | IG/1111/G |
| IG/1117/G | This was an application for a group of variations. A.7-Administrativechange-Deletionof manufacturing sites B.11.b.2.c.1-Change to importer,batch release arrangements and quality control testing of the FP - Replacementoradditionofamanufacturer responsible for importation and/or batch release - Notincludingbatchcontrol/testing                                                                                                                         | 05/07/2019 | 18/06/2020 | SmPC, Annex II, Labelling and PL |           |
|           | C.I.11.a - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation,including theRMP-Implementation of                                                                                                                                                                                                                                                                                                                    | 05/07/2019 | n/a        |                                  | IG/1112   |

<div style=\"page-break-after: always\"></div>

|         | wordingagreedbythecompetent authority                                                                                                                                                   |            |            |                            |                     |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------|---------------------|
| IG/1100 | A.7-Administrative change-Deletion of manufacturingsites                                                                                                                                | 24/05/2019 | n/a        |                            |                     |
| IG/1099 | A.7 - Administrative change - Deletion of                                                                                                                                               | 24/05/2019 | n/a        |                            | manufacturing sites |
| IG/1098 | B.III.1.a.2-Submission of a new/updated or deletionofPh.Eur.CertificateofSuitabilitytothe relevantPh.Eur.Monograph-Updated certificate from an alreadyapprovedmanufacturer              | 29/04/2019 | n/a        |                            |                     |
| IG/1056 | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of theAS                                                                         | 11/02/2019 | n/a        |                            |                     |
| N/0075  | Minorchangeinlabellingorpackageleafletnot connected with theSPC(Art.61.3Notification)                                                                                                   | 05/02/2019 | 18/06/2020 | PL                         |                     |
| IG/1017 | C.I.z-Changes(Safety/Efficacy)of Human and VeterinaryMedicinalProducts-Othervariation                                                                                                   | 11/12/2018 | 11/04/2019 | SmPC andPL                 |                     |
| IG/0986 | C.I.z - Changes (Safety/Efficacy) of Human and VeterinaryMedicinalProducts-Othervariation                                                                                               | 17/10/2018 | 11/04/2019 | Annex II, Labelling and PL |                     |
|         | This was an application for a group of variations. B.I.a.1.f-ChangeinthemanufacturerofASorofa startingmaterial/reagent/intermediateforAS- Changestoqualitycontroltestingarrangementsfor | 10/09/2018 | n/a        |                            | IG/0975/G           |

<div style=\"page-break-after: always\"></div>

|         | the AS -replacement or addition of a site where batch control/testing takes place B.III.1.a.1-Submission of a new/updated or deletionofPh.Eur.Certificate ofSuitabilityto the relevant Ph. Eur. Monograph - New certificate from analreadyapprovedmanufacturer   |            |            |                        |                                                           |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------------------------------|
| T/0068  | Transfer of Marketing Authorisation                                                                                                                                                                                                                              | 16/05/2018 | 25/06/2018 | SmPC, Labelling and PL |                                                           |
|         | A.5.b-Administrative change -Change in the name and/oraddressofamanufacturer/importerofthe finishedproduct,including quality control sites (excludingmanufacturerforbatchrelease)                                                                                | 21/06/2018 | n/a        |                        | IG/0947                                                   |
|         | C.I.3.a - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerningPSURorPASSortheoutcomeofthe assessmentdoneunderA45/46-Implementationof wording agreed by the competent authority                                      | 17/04/2018 | 25/06/2018 | SmPC and PL            | IG/0910                                                   |
| IG/0913 | B.II.c.1.a-Change in the specification parameters and/or limits of an excipient - Tightening of specification limits                                                                                                                                             | 26/03/2018 | n/a        |                        |                                                           |
|         | This was an application for a group of variations following a worksharing procedure according to Article20of CommissionRegulation(EC)No 1234/2008.                                                                                                               | 15/03/2018 | n/a        |                        | WS/1291/G B.1.b.1.c-Changein the specification parameters |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its corresponding test method B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its corresponding test method B.I.b.2.b-Change in test procedure forAS or startingmaterial/reagent/intermediate-Deletionof a test procedure for the AS or a starting material/reagent/intermediate,ifanalternativetest procedure is already authorised B.I.b.2.b -Change in test procedure for AS or startingmaterial/reagent/intermediate-Deletionof a test procedure for the AS or a starting material/reagent/intermediate,if an alternativetest procedure is already authorised B.I.b.2.b-Change in test procedure forAS or startingmaterial/reagent/intermediate-Deletionof a test procedure for the AS or a starting material/reagent/intermediate, if an alternative test procedure is already authorised B.I.b.2.b-ChangeintestprocedureforASor starting material/reagent/intermediate - Deletion of a test procedure for the AS or a starting material/reagent/intermediate,if analternativetest procedure is already authorised B.I.b.2.b-Change in testprocedure forAS or startingmaterial/reagent/intermediate-Deletionof a test procedure for the AS or a starting   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|         | material/reagent/intermediate,if an alternativetest procedure is already authorised B.I.b.2.b-Change in test procedure forAS or starting material/reagent/intermediate -Deletion of a test procedure for the AS or a starting material/reagent/intermediate,ifanalternativetest procedure is already authorised B.I.b.2.e - Change in test procedure for AS or startingmaterial/reagent/intermediate-Other changes to a test procedure(includingreplacement or addition) for the AS or a starting material/intermediate   |            |     |           |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------|
| IG/0863 | A.4-Administrative change-Change in the name and/oraddressof amanufactureroranASMFholder orsupplieroftheAS，startingmaterial,reagentor intermediateused in themanufacture of theASor manufacturerofanovelexcipient                                                                                                                                                                                                                                                                                                         | 01/12/2017 | n/a |           |
| IG/0826 | B.II1.1.a.2-Submission of a new/updated or deletion ofPh.Eur.Certificateof Suitability to the relevant Ph.Eur.Monograph-Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                                                         | 03/08/2017 | n/a |           |
|         | This was an applicationfor a group of variations. B.II.d.1.a -Change in the specification parameters and/orlimits of the finished product -Tightening of specification limits B.II.d.1.a-Change in the specificationparameters and/or limits of the finished product-Tightening of specification limits                                                                                                                                                                                                                   | 28/07/2017 | n/a | IG/0817/G |

<div style=\"page-break-after: always\"></div>

|                     | B.II.d.1.z-Change in the specificationparameters and/or limits of thefinishedproduct-Other variation B.II.d.2.a-Change in test procedure for the finished product-Minor changestoan approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a-Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a-Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.b - Change in test procedure for the finished product-Deletion of a testprocedureif an alternativemethod is already authorised B.II.d.2.b - Change in test procedure for the finished product - Deletion of a test procedure if an alternative method is already authorised   |            |     |                                |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------------------------|
| IG/0805             | A.7-Administrativechange-Deletionof manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 23/05/2017 | n/a |                                |
| PSUSA/10344 /201606 | PeriodicSafetyUpdateEUSingleassessment- amlodipine/valsartan,amlodipine/ hydrochlorothiazide/valsartan                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 09/03/2017 | n/a | PRACRecommendation-maintenance |
| IG/0776             | B.III.1.a.2-Submission of a new/updated or deletion ofPh.Eur.Certificateof Suitability to the relevantPh.Eur.Monograph-Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 23/02/2017 | n/a |                                |

<div style=\"page-break-after: always\"></div>

| WS/1080   | This was an application for a variation following a worksharing procedure according to Article 20 of CommissionRegulation(EC)No1234/2008. C.I.z - Changes (Safety/Efficacy) of Human and VeterinaryMedicinalProducts-Othervariation                                                                                                                                                                                                                                                                                                                                                         | 23/02/2017   | 30/01/2018   | SmPC and PL   |                                                 |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------|-------------------------------------------------|
|           | This was an applicationfor a group of variations. A.7-Administrativechange-Deletionof manufacturingsites A.7-Administrative change-Deletion of manufacturing sites A.7-Administrative change-Deletion of                                                                                                                                                                                                                                                                                                                                                                                    | 26/09/2016   | n/a          |               | IG/0733/G manufacturingsites                    |
|           | Thiswas anapplicationfor a groupof variations. B.I.a.1.f-Change in the manufacturer of ASor of a startingmaterial/reagent/intermediateforAS- Changestoqualitycontroltesting arrangementsfor theAS-replacementoradditionofasitewhere batch control/testing takes place B.I.a.1.f-Change in the manufacturer ofASor of a startingmaterial/reagent/intermediateforAS- Changes to quality control testing arrangements for theAS-replacementoradditionofasitewhere batch control/testing takes place B.I.b.2.a-Change in test procedure forAS or starting material/reagent/intermediate - Minor | 14/09/2016   | n/a          |               | IG/0727/G changes to an approved test procedure |

<div style=\"page-break-after: always\"></div>

|         | B.I.b.2.a - Change in test procedure for AS or startingmaterial/reagent/intermediate-Minor changes to an approved test procedure                                                                                                                                                                                  |            |            |    |                                 |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|---------------------------------|
| IG/0707 | B.I.a.1.f-Changein themanufacturer of ASor of a startingmaterial/reagent/intermediateforAS- Changes to quality control testing arrangements for theAS-replacementoradditionofasitewhere batchcontrol/testingtakesplace                                                                                            | 21/07/2016 | n/a        |    |                                 |
|         | B.III.1.a.2-Submission of a new/updated or deletionofPh.Eur.CertificateofSuitabilitytothe relevantPh.Eur.Monograph-Updated certificate from an already approved manufacturer                                                                                                                                      | 21/07/2016 | n/a        |    | IG/0706                         |
| N/0053  | Updateofthepackageleafletwithrevisedcontact details of the local representative for Germany. Minor changeinlabellingorpackageleafletnot connected with theSPC(Art.61.3 Notification)                                                                                                                              | 20/04/2016 | 30/01/2018 | PL |                                 |
|         | Thiswasanapplicationfor avariationfollowinga worksharingprocedureaccordingtoArticle20of CommissionRegulation(EC)No1234/2008. B.I.b.1.c-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its | 17/12/2015 | n/a        |    | WS/0704 correspondingtestmethod |

<div style=\"page-break-after: always\"></div>

| IG/0585/G   | This was an applicationfor a groupofvariations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 06/07/2015   | n/a        |             |                                                                                                                                                                                                                                                                                |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0710     | This was an application for a variation following a worksharingprocedureaccordingtoArticle20of CommissionRegulation(EC)No1234/2008. Changesrelatedtotheamlodipinecomponent Updateofsection4.2oftheSmPCtoincluderevised dosing recommendations in patients with hepatic impairment and in elderly patients. Changesrelatedtothevalsartancomponent Updateofsection4.8oftheSmPCtoupdatethe PreferredTermasperMedDRAversion17. ThePackageLeaflethasbeenupdatedaccordingly. In addition,theMAH tookthe opportunity to implementminoreditorialchangesintheSmPCand thePackageLeaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance | 26/03/2015   | 05/05/2015 | SmPC and PL | The posology section is updated to highlight that when switching eligiblehypertensivepatientswithhepatic impairmentorelderlyhypertensivepatientstoamlodipine orExforge,thelowestavailabledoseofamlodipine monotherapyorof theamlodipinecomponent,respectively, should be used. |

<div style=\"page-break-after: always\"></div>

|           | data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |            |            |             |                                       |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------|
| IG/0539   | C.I.1.a - Change(s) in the SPC, Labelling or PL intendedtoimplementtheoutcomeofaUnion referral procedure-Theproduct isnotcovered by thedefinedscopeoftheprocedure                                                                                                                                                                                                                                                                                                                                                                                                      | 27/03/2015 | 07/04/2016 | SmPC and PL |                                       |
| IG/0532/G | This was an application for a group of variations. B.III.1.a.2-Submission of a new/updated or deletion ofPh.Eur.CertificateofSuitability to the relevantPh.Eur.Monograph-Updated certificate from an already approved manufacturer B.III.1.a.2-Submission of a new/updated or deletion ofPh.Eur.Certificateof Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.II1.1.a.2-Submission of a new/updated or deletionofPh.Eur.CertificateofSuitability to the relevant Ph. Eur. Monograph - Updated certificate | 26/02/2015 | n/a        |             | from an already approved manufacturer |
|           | Thiswasanapplicationforagroupofvariations. A.4-Administrative change-Change in the name and/oraddressof amanufactureror anASMFholder or supplier of the AS, starting material, reagent or intermediateused in themanufacture of theASor manufacturer of a novel excipient B.I.b.1.b -Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent -Tightening of                                                                                                                                                              | 17/02/2015 | n/a        |             | IG/0528/G                             |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | specification limits B.I.b.1.c-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its corresponding test method                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |            |            |                        |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|
| IG/0527   | A.1-Administrative change -Change in the name and/or address of the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 17/02/2015 | 05/05/2015 | SmPC, Labelling and PL |
| WS/0616/G | Thiswas an applicationfor a group ofvariations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.1.c-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionof anew specification parameter to the specification with its corresponding test method B.I.b.1.d-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Deletionof anon- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.2.a-ChangeintestprocedureforASor startingmaterial/reagent/intermediate-Minor changestoanapprovedtestprocedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure | 18/12/2014 | n/a        |                        |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| WS/0634/G   | Thiswas an applicationfor a groupof variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Replacementof2 testmethodsfor anactive substance intermediate. Toincude a minor change in a test method for an activesubstanceintermediate. Toadd3testmethodsfor an activesubstance intermediate. To change the specification parameter for an active substanceintermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate- Other changestoa testprocedure(includingreplacement or addition) for the AS or a starting material/intermediate B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changestoanapprovedtestprocedure B.I.b.1.c-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specificationparameter to thespecificationwithits corresponding test method B.I.b.1.b-Change in the specification parameters and/or limits of an AS, starting   | 23/10/2014   | n/a   |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|

<div style=\"page-break-after: always\"></div>

|           | B.I.b.2.e-Change in test procedure forAS or startingmaterial/reagent/intermediate-Other changes to a testprocedure(includingreplacement or addition) for the AS or a starting material/intermediate B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its corresponding test method B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its correspondingtestmethod   |            |     |                                                                           |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|---------------------------------------------------------------------------|
| WS/0636/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. To implement changes in the manufacturing process of the active substance. B.I.a.2.z-Changes in the manufacturing process of theAS-Othervariation B.I.a.2.z-Changes in the manufacturing process of theAS-Other variation B.I.a.2.a - Changes in the manufacturing process of theAS-Minor change in the manufacturingprocess of theAS                                                                                                                                         | 23/10/2014 | n/a | To implement changes in the manufacturing process of the active substance |

<div style=\"page-break-after: always\"></div>

|           | the AS - Minor change in the manufacturing process of the AS B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its corresponding test method B.I.a.2.z-Changes in the manufacturing process of theAS-Other variation B.I.a.2.z-Changes in the manufacturingprocess of theAS-Othervariation B.I.a.2.a-Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS   |            |     |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| WS/0633/G | This was an application for a group of variations following a worksharing procedure according to Article20of CommissionRegulation(EC)No 1234/2008. Toreplace3 testmethodsfor anactive substance intermediate. To include a minor change to an approved test procedure for an active susbance intermediate. Toadd a testmethod or an activesubstance                                                                                                                                                                                                                                                                                                                                                                                                                       | 23/10/2014 | n/a |

<div style=\"page-break-after: always\"></div>

| Toadd2alternativetestmethodsforanactive substance intermediate. B.I.b.2.e - Change in test procedure for AS or startingmaterial/reagent/intermediate-Other changestoa testprocedure(includingreplacement or addition) for the AS or a starting material/intermediate B.I.b.2.a-Change in test procedure forAS or startingmaterial/reagent/intermediate-Minor changes to an approved test procedure B.I.b.1.c-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its corresponding test method B.I.b.2.e -Change in test procedure forAS or starting material/reagent/intermediate - Other changestoa testprocedure(includingreplacement or addition) for the AS or a starting material/intermediate B.I.b.2.e-Change in test procedure forAS or startingmaterial/reagent/intermediate-Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.1.c-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent -Addition of a new specification parameter to the specification with its corresponding test method   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its corresponding test method                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |            |            |             |                                                                                                                             |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------|
| WS/0635/G | This was an application for a group of variations following a worksharing procedure according to Article20ofCommissionRegulation(EC)No 1234/2008. ToaddanalternativemanufacturerofAS intermediates. Toincrease thebatchsizesforASintermediatesfor thenewmanufacturingsite To delete a manufacturing site for AS intermediates. B.I.a.1.z-Change in the manufacturer of ASor of a starting material/reagent/intermediate for AS- Other variation B.I.a.3.a -Change in batch size(including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size A.7-Administrative change-Deletion of manufacturingsites | 23/10/2014 | n/a        |             |                                                                                                                             |
| A31/0030  | On17April2013,furthertotheemergenceofnew evidencefrom thescientificliteratureondualRAS blockadetherapy andgiven theseriousnessofthe identified safety concerns, the Italian Medicines Agency (AIFA) initiated a review under Article 31 of CouncilDirective2001/83/EC,requestingthe                                                                                                                                                                                                                                                                                                                                                                                 | 22/05/2014 | 04/09/2014 | SmPC and PL | Forfurtherinformationpleasereferto theRenin- angiotensin-system (RAS)-acting agents Article 31 referral -Assessment report. |

<div style=\"page-break-after: always\"></div>

|        | PharmacovigilanceRiskAssessmentCommittee (PRAC) toissue a recommendation on thebenefit- risk of dual RAS blockade therapy through the combineduseofangiotensin-convertingenzyme inhibitors (ACE-inhibitors), angiotensin II receptor blockers (ARBs) or aliskiren and to determine whether any regulatory measures should be taken on themarketingauthorisationsof theproducts involved in this procedure.   |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0038 | Renewalofthemarketing authorisation.                                                                                                                                                                                                                                                                                                                                                                         | 25/04/2014 | 04/07/2014 | SmPC and PL | DafiroHCT is afixed dose combination(FDC)medicinal product containing amlodipine, a dihydropyridine derivative,valsartan, an angiotensinII antagonist and hydrochlorothiazide, a well-known thiazide diuretic. Exforge HCT is indicated for the treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of amlodipine, valsartan and hydrochlorothiazide(HCT),taken either as three single-component formulations or as a dual- component and a single-componentformulation. Theefficacydatacollectedsincetheinitial MAAonthe combination of amlodipine/valsartan/HCTZremain in accordancewiththepreviouscumulativeexperienceand theefficacyinformationpresentedintheSummaryof ProductCharacteristics(SmPC).Thesafety dataremainin accordance with the previous cumulative experience described in the PSURs and the safety information presented in the Core Data Sheet(CDS).The overall evaluationwasthattheproductbenefit/riskprofileremains |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |            |      | positive.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0517   | This was an application for a variation following a worksharing procedure according to Article 20 of CommissionRegulation(EC)No1234/2008. Updateofsection4.8oftheSmPCtoinclude the ADR'bullous dermatitis'. C.I.4 -Change(s)in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                     | 20/03/2014 | 04/07/2014 | SmPC | The MAH has submitted a comprehensive report with the purpose of reviewing the potential association of skin events with valsartan containing medications,including ExforgeandExforgeHCTandrespectiveclones.Itis consideredjustifiedtoupdatethelistofADRsinsection4.8 `undesirableeffects'of theExforgeSmPCandExforgeHCT SmPC and their respective clones based on additional informationfromasmallnumberofpost-marketingcases reportingbullousrashoccurringwithvalsartan.This amendmentdoesnotchangethebenefitriskbalancefor theseproductswhichremainspositive. |
| WS/0508/G | This was an application for a group of variations following a worksharingprocedure according to Article 20 of Commission Regulation (EC) No 1234/2008. -changeinthe specificationlimitsofsome intermediatesusedinthemanufactureof theactive substance, -additionofa newspecificationparameterswith theircorrespondingtestmethodstothespecification ofsomeintermediatesusedinthemanufactureof theactivesubstanceand -changeintestproceduresforsomeintermediates used inthemanufactureof the activesubstance. B.I.b.1.b-Change in the specificationparameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits | 20/02/2014 | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| B.I.b.1.b-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its corresponding test method B.I.b.1.c -Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its corresponding test method B.I.b.2.e -Change in test procedure forAS or startingmaterial/reagent/intermediate-Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e-Change in test procedure forASor starting material/reagent/intermediate- Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e -Change in test procedure forAS or startingmaterial/reagent/intermediate-Other changestoa testprocedure(includingreplacement or addition) for the AS or a starting material/intermediate B.I.b.2.e-Change in test procedure forAS or starting material/reagent/intermediate- Other   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|         | or addition) for the AS or a starting material/intermediate B.I.b.2.e -Change in test procedure forAS or starting material/reagent/intermediate- Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.1.c-Change in thespecificationparameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method                                 |            |     |           |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------|
| IG/0400 | A.5.b - Administrative change - Change in the name and/or addressofamanufacturer/importer of the finished product, including quality control sites (excludingmanufacturerforbatchrelease)                                                                                                                                                                                                                                                                                                                               | 20/01/2014 | n/a |           |
|         | This was an applicationfor a group of variations. A.7-Administrative change-Deletion of manufacturing sites A.7-Administrative change-Deletion of manufacturing sites B.I.a.1.f-Changein themanufacturerofASorof a startingmaterial/reagent/intermediateforAS- Changestoqualitycontroltestingarrangementsfor theAS-replacementoradditionofasitewhere batchcontrol/testingtakesplace A.4-Administrative change-Change in thename and/oraddressofamanufactureroranASMFholder orsupplieroftheAS，startingmaterial,reagentor | 12/12/2013 | n/a | IG/0390/G |

<div style=\"page-break-after: always\"></div>

|           | intermediateusedinthemanufactureoftheASor manufacturerofanovelexcipient                                                                                                                                                                                                                                                                                                               |            |            |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0376/G | Thiswas an applicationfor a groupof variations. B.1.b.1.b-Change in the specificationparameters and/or limits of an AS, starting material/intermediate/reagent-Tighteningof specification limits B.I.b.1.c-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its | 22/11/2013 | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| WS/0460   | Thiswas anapplicationfor avariationfollowing a worksharing procedure according to Article 20 of CommissionRegulation(EC)No1234/2008. Updateofsection4.5oftheSmPCtoincludefurther information regarding an interaction between valsartan and lithium. C.I.4 -Change(s)in the SPC, Labelling or PL due to newquality,preclinical,clinical orpharmacovigilance data                      | 21/11/2013 | 04/07/2014 | SmPC | The MAH has reviewed the clinical databases of four large outcomesstudies(Val-HeFT,Value,Valiant,andNavigator) foradverseeventreports of lithiumtoxicity.Further,the NovartisSafetyDatabase(ARGUS)wassearchedfor all caseswherebothvalsartanandlithiumwerereported as co-administered,andaliteraturesearchwasperformedfor published studies. Theavailabledatasuggestapossiblereversibleinteraction betweenvalsartanandlithium，althoughtheexact mechanismhasnotbeenestablished.Thedataidentified arelimitedandnoconfirmatoryevidencewasavailable from the clinical trialsperformed. TheSmPChasbeenupdatedtoinformprescribersof the factthatreversibleincreasesinserumlithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors, angiotensinIIreceptor antagonistsincludingvalsartan or |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |            |                                 | thiazides. Since renal clearance of lithium is reduced by thiazides, the risk of lithium toxicity may presumably be increasedfurtherwithvalsartan.Therefore,careful monitoringofserumlithiumconcentrationsis recommendedduringconcomitantuse.   |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|---------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0355 | B.III.1.a.2-Submission of a new/updated or deletion ofPh.Eur.CertificateofSuitability to the relevantPh.Eur.Monograph-Updatedcertificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 30/09/2013 | n/a        |                                 |                                                                                                                                                                                                                                                 |
| IG/0349 | B.II1.1.a.4-Submission of a new/updated or deletion ofPh.Eur.Certificateof Suitability to the relevant Ph. Eur. Monograph - Deletion of certificates (in case multiple certificatesexistper material)                                                                                                                                                                                                                                                                                                                                                                                                                                | 27/08/2013 | n/a        |                                 |                                                                                                                                                                                                                                                 |
| WS/0359 | This was an application for a variation following a worksharing procedure according to Article 20 of CommissionRegulation(EC)No1234/2008. Update ofSmPC sections 4.2,4.3,4.4 and 4.5 to reflectthattheconcomitantuseofAngiotensinII ReceptorBlockers(ARBs)orAngiotensin-Converting- Enzyme inhibitors (ACEi) with aliskiren is contraindicated inpatientswithrenal impairment and in patients with diabetes mellitus. Further, section 4.4 of the SmPC has been updated to inform prescribers that caution is required, and monitoring ofbloodpressure,renalfunctionandelectrolytesis recommended,when co-administering agentsacting | 27/06/2013 | 31/07/2013 | SmPC,Annex II, Labelling and PL | Please refer to theScientificDiscussion\"Exforge HCT- DafiroHCT-Copalia HCT-EMEA-H-C-xxxx-WS-359-AR\".                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

| The Package Leaflet has been updated accordingly. In addition, the MAH took the opportunity to update theSmPC,AnnexII and thePackageLeafletinline withthelatestQRDtemplate,toimplementminor editorialchangesinthelabellingandPackageLeaflet andtoaddthecontactdetailsof theCroatianlocal representative in the Package Leaflet. C.I.4-Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical orpharmacovigilance data   |            |     |                                 |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|---------------------------------|
| Thiswas anapplicationfor a groupof variations. B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.III.1.a.2-Submission of a new or updatedPh.Eur. Certificate of Suitability to therelevantPh.Eur. Monograph - Updated certificate from an already                                                                                                                              | 22/02/2013 | n/a | IG/0269/G approved manufacturer |
| C.I.z-Changes(Safety/Efficacy)of Human and VeterinaryMedicinalProducts-Othervariation                                                                                                                                                                                                                                                                                                                                                                                                 | 17/12/2012 | n/a | IG/0248                         |
| This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Tochangethespecifications andtestproceduresfor                                                                                                                                                                                                                                                                                | 13/12/2012 | n/a | WS/0333/G                       |

<div style=\"page-break-after: always\"></div>

| hydrochlorothiazide(the active substance)and for an intermediateused in themanufacture of the active substance hydrochlorothiazide. B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Tighteningof specification limits B.I.b.1.b -Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Tighteningof specification limits B.I.b.1.c-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specificationparametertothespecificationwithits corresponding test method B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Deletionofanon- significant specification parameter (e.g. deletion of anobsoleteparameter) B.I.b.1.z-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Othervariation B.I.b.2.b-Change in test procedure for AS or startingmaterial/reagent/intermediate-Deletionof a test procedure for the AS or a starting material/reagent/intermediate,ifanalternativetest procedure is already authorised B.I.b.2.e -Change in test procedure forAS or   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| changesto a testprocedure(includingreplacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or startingmaterial/reagent/intermediate-Other changestoa testprocedure(includingreplacement or addition) for the AS or a starting material/intermediate B.I.b.2.a -Change in test procedure for AS or startingmaterial/reagent/intermediate-Minor changes to an approved test procedure B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Othervariation B.I.b.2.a-Change in test procedure forAS or starting material/reagent/intermediate - Minor changestoanapprovedtestprocedure B.I.b.2.e -Change in test procedure forAS or startingmaterial/reagent/intermediate-Other changestoa testprocedure(includingreplacement or addition) for the AS or a starting material/intermediate B.I.b.2.e -Change in test procedure forAS or startingmaterial/reagent/intermediate-Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.a-Change in testprocedure forAS or startingmaterial/reagent/intermediate-Minor   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

<!-- image -->

| IG/0233   | B.III.1.a.2 -Submission of a new or updated Ph.Eur. Certificate of Suitability to the relevantPh.Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 13/11/2012   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0252/G | This was an application for a group of variations following a worksharing procedure according to Article20of CommissionRegulation(EC)No 1234/2008. WS-0252-Gwasagroupofvariationsconsistingof two Type II variations following a worksharing procedure according to Article 20 of Commission Regulation(EC)No1234/2008asfollows: Variation1:Updateofsection4.4of theSmPC to add a new warning regarding the risk of 'angioedema'related tothevalsartancompound. Further, the MAH took the opportunity to update the wording of the existing warnings in section 4.4 of the SmPC('renal artery stenosis','heart failure',and 'aorticandmitralvalvestenosis')forincreased clarity.ThePackageLeaflet hasbeen updated accordingly; Variation2:Updateofsections4.2,4.3,4.4,4.7, 4.8,5.1and5.2oftheSmPCtoharmonisethe existingwordingrelatedtotheamlodipinecompound inlinewiththelatestSmPCofNorvasc(amlodipine monotherapy) approved as part of a recent article 30 procedure EMEA/H/A-30/1288. The Package Leaflet hasbeen updated accordingly.In addition,theMAH tooktheopportunitytoupdatethecontactdetailsfor the local representative for Malta in the Package | 20/09/2012   | 31/10/2012 | SmPC and PL | Thesafetyupdateof theSmPCandPackageLeafletwas basedonareviewoftheMAH'ssafetyandclinicaltrialdata bases,published literatureforboth the amlodipine and valsartancomponents,arecommendationbytheUSFDA as well as the recent revised and harmonised amlodipine monotherapy(Norvasc)productinformation thatwas agreed by the CHMP as part of the article 30 referral procedure EMEA/H/A-30/1288 on 21 July 2011. TheMAHpresentedanextensiveanalysisofboth 'angioedema requiring intubation' and 'previous angioedema with or withoutACE-inhibitoruse',based on datafrom theirsafetydatabaseand theclinicaltrial database. In addition, the MAH provided the outcome of a literaturesearch.Fromthesafetydatabase,42patientsout of1469'angioedema'reports(2.86%)requiredintubation. In the clinical trial database there was a small number of patients with angioedema who also experienced an AE related to'respiratory distress'(e.g.laryngospasm, enotracheal intubation, laryngeal edema, mechanical ventilation, tracheostomy, respiratory distress, wheezing). Thepercentageofpatientswithapasthistoryof angioedemaacross all studieswassmall.Atotalof86 patients out of the 1469 reports from the safety database hadapreviousepisodeof angioedema,in40of thesethe previousangioedemaepisodewasassociatedwiththeuse ofanACE-inhibitorandin46patientsitwasnot.In5/40 and12/46cases,respectively,theindexeventwasworse |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | Leaflet. C.I.4 -Variations related to significant modifications of theSPCdue inparticular to newquality,pre- clinical, clinical or pharmacovigilance data C.I.4-Variationsrelatedto significant modifications of theSPCdueinparticular tonewquality,pre- clinical,clinical orpharmacovigilance data   |            |            |             | than theprevious one.This does not indicate that a more severeangioedemaeventthanthatoccurringinassociation with anACE-inhibitormustnecessarilybeexpectedwhen valsartanis givenfor treatment subsequently. Accordingtotheliterature,thefrequencyofangioedema associatedwithARBsseemslowerthanthatobservedwith ACE-inhibitors.Althoughsomepublicationssuggest a higher risk of angioedema with ARBs in patients who had already experienced angioedema with ACE-inhibitors, the frequency datareported in theliterature are inconsistent. However, as angioedema is apotentially life-threatening andfataladverseeffect,thereviewedliteraturehighlights thatACE-inhibitorsorARBsshouldbeusedwithcautionin patients with any history of this condition. ThesafetydataprovidedbytheMAH isregarded as sufficient in order to justify the proposed warning on angioedema'insection4.4of theSmPC.It shouldalsobe noted thatawarningregardingangioedema'is already included in the SmPC for Diovan (valsartan monotherapy). Additionalchangestothewordingofwarningsalready included inSmPCsection4.4(\"renal arterystenosis\", \"heartfailure”and\"aorticand mitral valve stenosis\")were alsomadeaspartof thisprocedure inordertoprovide further clarity to the health careprofessional. Inaddition,theMAHtooktheopportunity toupdatethe amlodipinesectionsoftheSmPCinaccordancewiththe harmonised product informationfor Norvasc(amlodipine   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0250/G | Thiswasanapplicationforagroupofvariations followingaworksharingprocedureaccordingto Article20ofCommissionRegulation(EC)No                                                                                                                                                                             | 19/07/2012 | 30/08/2012 | SmPC and PL | Administrationofamlodipinewithgrapefruit orgrapefruit juice is not recommended as bioavailability may be increasedinsomepatients,resultinginincreasedblood                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| 1234/2008. WS-0250-Gwasagroupofvariationsconsistingof two Type II variations following a worksharing procedure according toArticle 20of Commission Regulation(EC)No1234/2008asfollows: Variation1:Updateofsection4.5of theSmPCto addinformation aboutthepotential druginteraction between amlodipine and simvastatin,and update of theexistingamlodipineinformationinsection4.5in linewiththereviseddrug interactionssectionfor Norvasc(amlodipine monotherapy).ThePackage Leaflet has been updated accordingly; Variation2:Updateofsection4.5oftheSmPCto addinformation aboutthepotential druginteraction betweenvalsartanandinhibitorsoftheuptake transporter (rifampicin, ciclosporin) or efflux transporter(ritonavir).ThePackageLeaflet hasbeen updated accordingly. C.I.4-Variations related to significant modifications of theSPC due inparticular to newquality,pre- clinical,clinicalorpharmacovigilancedata C.I.4-Variationsrelatedtosignificantmodifications   | pressure lowering effects. Concomitantuse of amlodipinewithstrong ormoderate CYP3A4inhibitors(protease inhibitors,azole antifungals, macrolides like erythromycin or clarithromycin, verapamil or diltiazem) may give rise to significant increase in amlodipine exposure. The clinical translation of these pharmacokinetic variations may be more pronounced in the elderly.Clinical monitoring and doseadjustmentmay thus be required. ThereisnodataavailableregardingtheeffectofCYP3A4 inducersonamlodipine.TheconcomitantuseofCYP3A4 inducers (e.g. rifampicin, Hypericum perforatum) may give alowerplasmaconcentrationofamlodipine.Amlodipine shouldbeusedwithcautiontogetherwithCYP3A4 inducers. Co-administration of multiple doses of 10 mg amlodipine with80mgsimvastatinresultedina77%increasein exposure tosimvastatincompared tosimvastatin alone.It is recommended tolimit the dose of simvastatin to 20 mg daily in patients on amlodipine. In animals,lethalventricularfibrillation and cardiovascular collapseareobservedinassociationwithhyperkalaemia after administration ofverapamil andintravenous dantrolene.Due torisk of hyperkalaemia,it is   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                   |            |            | indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1 and of the hepatic efflux transporter MRP2.Co-administration ofinhibitors of the uptake transporter(rifampicin,ciclosporin)oreffluxtransporter (ritonavir)may increase the systemicexposure to valsartan.   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0209/G | This was an application for a group of variations. C.I.9.b-Changestoanexistingpharmacovigilance system as described in the DDPS - Change in the contactdetailsoftheQPPV C.I.9.h-Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system                                                                      | 17/08/2012 | n/a        |                                                                                                                                                                                                                                                                                              |
| WS/0282   | This was an application for a variation following a worksharing procedure according to Article 20 of CommissionRegulation(EC)No1234/2008. toadd anewspecificationparameterforimpuritiesin the active substance. B.I.b.1.c-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its correspondingtestmethod | 19/07/2012 | 19/07/2012 |                                                                                                                                                                                                                                                                                              |
| IG/0200/G | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                | 13/07/2012 | n/a        |                                                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| B.I.a.1.f-ChangeinthemanufacturerofASorofa starting material/reagent/intermediate for AS - Changestoqualitycontroltesting arrangementsfor theAS-replacementoradditionofasitewhere batch control/testing takes place B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for theAS-replacementoradditionofasitewhere batchcontrol/testing takesplace B.I.a.1.f-Change in the manufacturer of ASor of a startingmaterial/reagent/intermediateforAS- Changestoqualitycontroltestingarrangementsfor theAS-replacementoradditionofasitewhere batchcontrol/testingtakesplace B.I.a.1.f-Change in the manufacturer ofASor of a startingmaterial/reagent/intermediateforAS- Changes to quality control testing arrangements for the AS-replacement or addition of a site where batch control/testing takes place B.I.a.1.f-Change in themanufacturer ofASor of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for theAS-replacementoradditionofasitewhere batchcontrol/testing takesplace B.Ill.1.a.2-Submissionofa neworupdatedPh.Eur. Certificateof Suitability totherelevantPh.Eur. Monograph-Updatedcertificatefromanalready approved manufacturer A.5.b-Administrative change-Change in the name and/oraddressof amanufacturerof thefinished   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | manufacturerforbatchrelease)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |            |            |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0253/G | This was an application for a group of variations following a worksharing procedure according to Article20ofCommissionRegulation(EC)No 1234/2008. WS-0253-G is a groupof twovariations(one type II &onetypeIB)followingaworksharingprocedureas follows: - Type II variation: Update of section 4.6 of the SmPCwithwordingonfertilityinlinewiththeSmPC forDiovan(valsartanmonotherapy)and5.3of the SmPCtoimplementthechangestotheSmPCfor Diovan that was approved as part of a recent Article 30 (referral) procedure; - Type IB variation: Update of sections 4.6 and 5.3 of theSmPCtoimplementthechangestotheSmPCfor Norvasc(amlodipine monotherapy) that was approved as part of a recent Article 30 (referral) procedure. C.I.1.b - Change in the SPC, Labelling or PL following a referral procedure - The product is not covered by the defined scope of the referral but the change implementstheoutcomeofthereferralandnonew additionaldataaresubmittedbytheMAH C.I.z-Changes(Safety/Efficacy)of Human and VeterinaryMedicinal Products-Other variation | 24/05/2012 | 28/06/2012 | SmPC | The safety of amlodipine in human pregnancy has not been established.Reproductivestudiesinratsandmicehave shown delayed date of delivery,prolonged duration of labouranddecreasedpupsurvival atdosages approximately 50 times greater than the maximum recommendeddosageforhumansbasedonmg/kg.Use in pregnancy is only recommended when there is no safer alternative andwhenthediseaseitselfcarriesgreaterrisk for themother andfoetus. Reversiblebiochemical changesintheheadofspermatozoa havebeenreported insomepatientstreatedbycalcium channelblockers.Clinical data are insufficientregarding the potential effect of amlodipine on fertility. There was no effectonthefertilityofratstreatedwith amlodipine(males for 64 days and females 14 days prior to mating) at doses up to 10 mg/kg/day (8 times* the maximum recommended human doseof10mg onamg/m2basis).In anotherrat studyinwhichmaleratsweretreatedwithamlodipine besilatefor30daysatadosecomparablewiththehuman dose based on mg/kg, decreased plasma follicle-stimulating hormone andtestosteronewerefoundaswell asdecreases inspermdensityandinthenumberofmaturespermatids andSertoli cells. Ratsandmice treatedwith amlodipineinthe dietfor two years, at concentrations calculated to provide daily dosage levels of0.5,1.25,and 2.5mg/kg/day showedno evidence of carcinogenicity.The highest dose(for mice, similar to, andforratstwice*themaximumrecommendedclinical dose of 10 mg on a mg/m2 basis) was close to the maximumtolerateddoseformicebutnotforrats. |

<div style=\"page-break-after: always\"></div>

| Mutagenicitystudiesrevealednodrugrelatedeffects at eitherthegeneorchromosomelevels. * Based on patient weight of 50 kg Valsartanhadnoadverseeffectsonthereproductive performance of male or female rats at oral doses up to 200 mg/kg/day. This dose is 6 times the maximum recommendedhumandoseonamg/m2basis(calculations assume an oral dose of 320 mg/day and a 60-kg patient). Non-clinicaldatareveal nospecial hazardforhumans based on conventional studies of safety pharmacology, repeated dosetoxicity,genotoxicity,carcinogenicpotential. In rats, maternally toxic doses (600 mg/kg/day) during the last days of gestation and lactation led to lower survival, lower weight gain and delayed development (pinna detachment and ear-canal opening) in the offspring (see section 4.6).These doses in rats (600 mg/kg/day)are approximately 18 times the maximum recommended human doseon a mg/m2basis(calculations assume an oral dose of 320 mg/day and a 60-kg patient). In non-clinical safety studies,high doses of valsartan(200 to600mg/kgbodyweight)caused inrats areduction of red blood cell parameters (erythrocytes, haemoglobin, haematocrit)andevidenceofchangesinrenal haemodynamics(slightlyraised plasma urea, and renal tubular hyperplasia and basophilia in males). These doses in rats (200 and 600 mg/kg/day) are approximately 6 and 18timesthemaximumrecommendedhumandoseona mg/m2 basis (calculations assume an oral dose of 320 mg/day and a 60-kg patient). In marmosets atsimilar doses,the changeswere similar though more severe, particularly in the kidney where the   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |            |            | urea and creatinine. Hypertrophy of the renal juxtaglomerular cells was also seeninbothspecies.Allchangeswereconsideredtobe caused by the pharmacological action of valsartan which produces prolonged hypotension, particularly in marmosets. For therapeutic doses of valsartan in humans, the hypertrophy of the renal juxtaglomerular cells does not seemtohaveanyrelevance.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0172 | This was an application for a variation following a worksharingprocedureaccordingtoArticle20of CommissionRegulation(EC)No1234/2008. Update of thesafety andpharmacokinetic informationintheSmPCrelatedtothe hydrochlorothiazidecomponentofthefixed-dose combination. As a consequence, sections 4.2, 4.4, 4.5,4.6,4.8 and5.2oftheSmPChavebeen updated and the Package Leaflet has been updated accordingly. In addition, the MAH has taken the opportunity to implement editorial changes in the SmPC and Package Leaflet and to update the contact details of the local representatives in the Package Leaflet. C.I.4 -Variations related to significant modifications of theSPC due inparticular to new quality,pre- clinical, clinical orpharmacovigilance data | 24/05/2012 | 28/06/2012 | SmPC andPL | TheMAHhasundertakenthefollowingin-depthreviewof theclinicalsafety andclinicalpharmacologyinformation available to date on the HCTZ component of the fixed-dose combination: Review of Esidrex(containing HCTZ,first authorised in Switzerland in1958,nationally authorised in39countries) PSURs 1-6(1 0ct 1989-31 Dec2009); Cases/eventsfromtheMAHsGlobalSafetyDatabase (NGSD):NGSDwasreviewed cumulatively(cut-off date13 Apr2010)for allcases(spontaneousreportsincluding literaturereportsaswellasseriousadverseeventsfrom clinical trials)toidentify any unlisted event clustersfor Esidrex.Nonewunlistedeventclusterwasidentifiedinthe summarytabulationfromthesafetydatabasesearch; Literaturereview:Major drugreferencebooks,including Martindale (HCTZ) and Meyler's side effects(thiazide diuretics), were reviewed for unlisted adverse reactions, andbridgingliteraturesearchesuptothecut-offdateof13 Apr2010wereperformedasperPSURsearchcriteria (publicationdatefrom thePSUR6cut-off date:31Dec 2009). As a consequence,sections 4.2,4.4,4.5,4.6,4.8 and 5.2 of theSmPChavebeenupdatedand thePackageLeaflet |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                         |            |     | has been updated accordingly. Section4.4oftheSmPChasbeenupdatedtoincludeanew warningonthepotentialriskof'acuteangle-closure glaucoma' associated with the use of hydrochlorothiazide. Hydrochlorothiazide,asulphonamide,hasbeenassociated withanidiosyncraticreactionresultinginacutetransient myopia and acute angle-closure glaucoma. Symptoms includeacuteonsetofdecreasedvisualacuityorocular pain and typically occur within hours to a week of treatment initiation.Untreated acute-angle closure glaucoma can lead to permanent vision loss. The primary treatment is to discontinue hydrochlorothiazide asrapidlyaspossible.Promptmedicalorsurgicaltreatment mayneedtobeconsideredif theintraocularpressure remainsuncontrolled.Riskfactorsfordeveloping acute angle closure glaucoma may include a history of sulphonamide or penicillin allergy. Further,thefollowingnewADRshavebeenadded to section 4.8 of the SmPC: asthenia, pyrexia, erythema multiforme，aplasticanemia，renaldisorder,musclespasm   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0190/G | Thiswas an applicationfor a groupofvariations. B.IIl.1.a.1-Submissionof aneworupdatedPh.Eur. Certificateof Suitabilityto therelevantPh.Eur. Monograph-Newcertificatefrom an already approved manufacturer B.III.1.a.2 - Submission of a new or updated Ph. Eur. CertificateofSuitabilitytotherelevantPh.Eur. Monograph-Updatedcertificatefrom analready | 15/06/2012 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

| B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Deletionofanon- significant specification parameter (e.g. deletion of anobsoleteparameter)                                                                                                                                                                                                                                                                                          |            |     |                                                     |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------------------------|
| Thiswas anapplicationfor a group of variations. C.I.9.e-Changes to anexistingpharmacovigilance system as described in the DDPS - Changes in the majorcontractualarrangementswithotherpersons or organisationsinvolvedinthefulfilment of pharmacovigilanceobligationsanddescribedinthe DD C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to theDDPSthat doesnotimpacton the operationof the pharmacovigilance system                             | 22/02/2012 | n/a | IG/0148/G                                           |
| Thiswas an applicationfor a group of variations. B.II.b.1.e-Replacement or addition of a manufacturing sitefortheFp-Sitewhere any manufacturing operation(s) take place, except batch- release,batchcontrol,primary andsecondary packaging, for non-sterile medicinal products B.II.b.2.a - Change to batch release arrangements and quality control testing of the FP - Replacement or addition of a site where batch control/testing takes place A.5.b - Administrative change - Change in the name | 11/11/2011 | n/a | IB/0009/G and/oraddressofamanufacturerofthefinished |

<div style=\"page-break-after: always\"></div>

|           | product, including quality control sites (excluding manufacturerforbatchrelease) A.5.b -Administrative change -Change in the name and/oraddressof amanufacturerof thefinished product, including quality control sites (excluding manufacturerforbatchrelease) B.II.b.3.a-Change in the manufacturing process of the finished product - Minor change in the manufacturingprocessof animmediatereleasesolid oraldosageformororalsolutions B.II.b.3.a-Change in the manufacturing process of thefinishedproduct-Minor change in the manufacturingprocessofanimmediatereleasesolid oraldosageformororalsolutions B.II.b.3.a-Change in the manufacturing process of thefinishedproduct-Minor change in the manufacturing process of an immediate release solid oral dosage form or oral solutions B.II.b.3.a - Change in the manufacturing process of thefinishedproduct-Minor change in the manufacturingprocessofanimmediatereleasesolid oraldosageformororalsolutions B.II.b.4.a -Change in the batch size (including batch sizeranges)of the finishedproduct-Up to10-fold comparedtothecurrentlyapprovedbatchsize B.II.b.5.z-Change to in-process tests or limits applied during the manufacture of the finished   |            |     |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IG/0088/G | This was an applicationfor a group of variations. C.I.9.e-Changestoanexistingpharmacovigilance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 11/07/2011 | n/a |

<div style=\"page-break-after: always\"></div>

|           | system as described in the DDPS - Changes in the major contractual arrangements with other persons ororganisationsinvolvedinthefulfilmentof pharmacovigilanceobligationsanddescribedinthe DD C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) totheDDPSthatdoesnotimpactontheoperationof the pharmacovigilance system   |            |            |                   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------------|
| IG/0073/G | Thiswasanapplicationforagroupofvariations. B.I.a.2.a-Changes in the manufacturingprocess of theAS-Minorchangeinthemanufacturingprocess of the AS B.I.b.1.c-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent -Addition of a new specification parameter to the specification with its correspondingtestmethod           | 16/06/2011 | n/a        |                   |
| N/0008    | Minor changeinlabellingorpackageleafletnot connectedwiththeSPC(Art.61.3Notification)                                                                                                                                                                                                                                                                                        | 31/05/2011 | n/a        | PL                |
| IG/0058   | B.IIl.1.a.2-SubmissionofaneworupdatedPh.Eur. Certificate of Suitability to the relevantPh.Eur. Monograph-Updatedcertificatefrom an already approvedmanufacturer                                                                                                                                                                                                             | 13/04/2011 | n/a        |                   |
| WS/0097   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.                                                                                                                                                                                                                               | 17/02/2011 | 17/03/2011 | SmPC and Annex II |

<div style=\"page-break-after: always\"></div>

|           | Toextend theshelf-lifeof thefinishedproductfrom 18monthsto 2years.The MAH has also taken the opportunity to update the Annex II.B with the latest wording as per the October and November 2010 CHMPproceduralannouncement. B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of thefinishedproduct-Aspackagedforsale (supported by real time data)                                                                                                                                                                                                                                                                                                                                                                                                                |            |            |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|
| WS/0088/G | Thiswas anapplicationfor agroupofvariations followingaworksharingprocedure accordingto Article20of CommissionRegulation(EC)No 1234/2008. to change the specification limit for an impurity in the active substance ; toaddnewtestproceduresfortheactivesubstance toaddnewspecificationsin the activesubstance todelete atestprocedureforthe activesubstance. B.I.b.1.c -Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specificationparametertothespecificationwithits corresponding test method B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.2.e - Change in test procedure for AS or | 17/02/2011 | 17/02/2011 |

<div style=\"page-break-after: always\"></div>

|           | startingmaterial/reagent/intermediate-Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate- Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.b -Change in test procedure forAS or startingmaterial/reagent/intermediate-Deletionof a test procedure for the AS or a starting material/reagent/intermediate,ifanalternativetest procedure is already authorised B.I.b.2.e-Change in test procedure forAS or startingmaterial/reagent/intermediate-Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate   |            |     |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IG/0032/G | Thiswas an applicationfor a group of variations. ToupdatetheDetailedDescriptionofthe PharmacovigilanceSystem(DDPS)toversion9.0,to include: -achangeinthedeputyof theQualifiedPersonfor Pharmacovigilance (QPPV); -a change in themajor contractual arrangements. - administrative changes not impacting the operation of the pharmacovigilance system. AnnexII.Bhas alsobeenupdated with thelatest wording asper October 2010 CHMPprocedural                                                                                                                                                                                                                                                                                                                                                              | 21/12/2010 | n/a |

<div style=\"page-break-after: always\"></div>

|           | announcement. C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the back-up procedure of the QPPV C.I.9.e-Changes to anexistingpharmacovigilance system as described in the DDPS - Changes in the majorcontractual arrangementswithotherpersons or organisations involved in the fulfilment of pharmacovigilance obligations anddescribed inthe DD C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system                          |            |     |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IB/0007/G | This was an application for a group of variations. B.I.a.1.z-Change in the manufacturer of ASor of a startingmaterial/reagent/intermediateforAS-Other variation A.4-Administrative change -Change in the name and/oraddressof amanufacturerorsupplierofthe AS，startingmaterial,reagentorintermediateused in themanufactureof theAS A.7-Administrativechange-Deletionof manufacturingsites B.I.a.1.f-Change in themanufacturer of ASor of a startingmaterial/reagent/intermediateforAS- Changestoqualitycontroltesting arrangementsfor theAS-replacementoradditionofasitewhere batch control/testing takes place | 27/10/2010 | n/a |

<div style=\"page-break-after: always\"></div>

|           | B.I.a.1.a-Change in the manufacturer of AS or of a startingmaterial/reagent/intermediateforAS-The proposedmanufacturerispartofthesame pharmaceutical group as the currently approved manufacturer A.4-Administrativechange-Change in thename and/oraddressofamanufacturerorsupplierofthe AS, starting material, reagent or intermediate used in themanufactureof theAS   |            |            |           |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------|
| I1/0005   | Minor change in the manufacturing process of the activesubstancevalsartan. B.I.a.2.z-Changes in the manufacturing process of theAS-Othervariation                                                                                                                                                                                                                        | 23/09/2010 | 27/09/2010 |           |
| IA/0006/G | This was an application for a group of variations. B.II.b.1.a-Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.b-Replacement or addition of a manufacturing site for the Fp - Primary packaging site                                                                                                                       | 20/09/2010 | n/a        |           |
|           | This was an application for a group of variations. B.I.b.2.e - Change in test procedure for AS or startingmaterial/reagent/intermediate-Other changes to a testprocedure(includingreplacement or addition) for the AS or a starting material/intermediate                                                                                                                | 22/06/2010 | n/a        | IB/0003/G |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| B.I.b.2.e -Change in test procedure forAS or startingmaterial/reagent/intermediate-Other changestoa testprocedure(includingreplacement or addition) for the AS or a starting material/intermediate A.7-Administrativechange-Deletionof manufacturing sites B.III.1.a.2-Submission of a new or updated Ph.Eur. Certificate of Suitability to therelevantPh.Eur. Monograph-Updated certificatefrom an already approved manufacturer B.III.1.a.1 -Submission of a new or updated Ph.Eur. CertificateofSuitabilitytotherelevantPh.Eur. Monograph - New certificate from an already approved manufacturer B.III.1.a.2-Submission of a new or updated Ph.Eur. Certificate of Suitability to the relevant Ph.Eur. Monograph-Updatedcertificatefrom analready approved manufacturer B.I.b.1.c-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its correspondingtestmethod B.I.b.2.a -Change in test procedure for AS or startingmaterial/reagent/intermediate-Minor changestoanapprovedtestprocedure B.I.b.1.c-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its corresponding testmethod   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           | B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.d-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Deletionofanon- significant specification parameter (e.g. deletion of an obsolete parameter)                                                                                                                                             |            |            |          |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|
| IB/0002/G | Thiswas an applicationfor a group of variations. B.II.d.1.a - Change in the specification parameters and/orlimits of the finished product-Tightening of specification limits B.II.d.1.c-Change in the specification parameters and/orlimitsof thefinishedproduct-Addition of a newspecificationparametertothespecificationwith itscorrespondingtestmethod B.II.d.1.d-Change in the specificationparameters and/orlimitsof thefinishedproduct-Deletion of a non-significant specificationparameter(e.g. deletion | 22/06/2010 | n/a        |          |
| IA/0004   | B.I.a.3.a-Changeinbatchsize(includingbatchsize ranges)ofASorintermediate-Upto10-fold increasecomparedtothecurrentlyapprovedbatch size                                                                                                                                                                                                                                                                                                                                                                           | 18/06/2010 | n/a        |          |
| I1/0001   | Changes to QPPV UpdateofSummaryofProductCharacteristics UpdateofDDPS(Pharmacovigilance)                                                                                                                                                                                                                                                                                                                                                                                                                         | 18/02/2010 | 23/03/2010 | Annex II |

<div style=\"page-break-after: always\"></div>